MedTrace Logo

Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome

NCT00815659 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2011-08-31

Study results available
· View outcomes & findings →

Summary

The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol, triglyceride) in patients with metabolic syndrome.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

rosuvastatin

medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.

Sponsors & Collaborators

Principal Investigators

  • Dilek Ural, MD, Prof · Kocaeli University Faculty of Medicine Cardiology Dept

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00815659 on ClinicalTrials.gov